DENNIS MICHAEL MCNAMARA
Medical Practice in Washington
License number
Pennsylvania MD053025L
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
2
Washington
Venetia, PA 15367
Venetia, PA 15367
Professional information
Genetic Risk Assessment In Heart Failure: Impact Of Genetic Variation Of Aldosterone Synthase Promoter Polymorphism
US Patent:
2009025, Oct 8, 2009
Filed:
Oct 4, 2006
Appl. No.:
12/088924
Inventors:
Manuel Worcel - Boston MA, US
Michael Sabolinski - Franklin MA, US
Sang W. Tam - Dover MA, US
Dennis M. McNamara - Venetia PA, US
Michael Sabolinski - Franklin MA, US
Sang W. Tam - Dover MA, US
Dennis M. McNamara - Venetia PA, US
Assignee:
NitroMed, Inc. - Lexington MA
University of Pittsburgh of the Commonwealth System of Higher Education - Pittsburgh PA
University of Pittsburgh of the Commonwealth System of Higher Education - Pittsburgh PA
International Classification:
A61K 31/56, A61K 31/34, A61K 31/502, A61K 31/40, A61K 31/403, A61K 31/352, A61P 9/00
US Classification:
514171, 514470, 514248, 514423, 514412, 514456
Abstract:
The invention provides methods for (a) reducing mortality associated with heart failure; (b) improving oxygen consumption; (c) treating heart failure; (d) treating hypertension; (e) improving the quality of life in a heart failure patient; (f) inhibiting left ventricular remodeling; (g) reducing hospitalizations related to heart failure; (h) improving exercise tolerance; (j) increasing left ventricular ejection fraction; (Ic) decreasing levels of B-type natriuretic protein; (l) treating renovascular diseases; (m) treating end-stage renal diseases; (n) reducing cardiomegaly; (o) treating diseases resulting from oxidative stress; (p) treating endothelial dysfunctions; (q) treating diseases caused by endothelial dysfunctions; or (r) treating cardiovascular diseases; in a patient in need thereof, wherein the patient has a −344 (T/T) polymorphism or a −344 (C/C) polymorphism in an aldosterone synthase CYP11B2 gene, comprising administering to the patient (i) at least one antioxidant compound or a pharmaceutically acceptable salt thereof; (ii) at least one nitric oxide enhancing compound; and (iii) optionally the best current therapy for the treatment of cardiovascular diseases. In one embodiment the antioxidant is a hydralazine compound or a pharmaceutically acceptable salt thereof and the nitric oxide enhancing compound is isosorbide dinitrate and/or isosorbide mononitrate.
Genetic Risk Assessment In Heart Failure: Impact Of Genetic Variation Of Beta 1 Adrenergic Receptor Gly389Arg Polymorphism
US Patent:
2009019, Jul 30, 2009
Filed:
Oct 4, 2006
Appl. No.:
12/088923
Inventors:
Manuel Worcel - Boston MA, US
Michael L. Sabolinski - Franklin MA, US
Sang W. Tam - Dover MA, US
Dennis M. McNamara - Venetia PA, US
Michael L. Sabolinski - Franklin MA, US
Sang W. Tam - Dover MA, US
Dennis M. McNamara - Venetia PA, US
Assignee:
NitroMed Inc. - Lexington MA
University of Pittsburgh of the Commonwealth System of Higher Education - Pittsburgh PA
University of Pittsburgh of the Commonwealth System of Higher Education - Pittsburgh PA
International Classification:
A61K 31/56, A61K 31/34, A61K 31/40, A61K 31/403, A61K 31/137, A61K 31/352
US Classification:
514171, 514470, 514423, 514412, 514649, 514456, 514411
Abstract:
The invention provides methods for (a) reducing mortality associated with heart failure; (b) improving oxygen consumption; (c) treating heart failure; (d) treating hypertension; (e) improving the quality of life in a heart failure patient; (f) inhibiting left ventricular remodeling; (g) reducing hospitalizations related to heart failure; (h) improving exercise tolerance; (j) increasing left ventricular ejection fraction; (k) decreasing levels of B-type natriuretic protein; (l) treating renovascular diseases; (m) treating end-stage renal diseases; (n) reducing cardiomegaly; (o) treating diseases resulting from oxidative stress; (p) treating endothelial dysfunctions; (q) treating diseases caused by endothelial dysfunctions; or (r) treating cardiovascular diseases; in a patient in need thereof, wherein the patient has a Arg389Arg polymorphism and/or a Gly389Gly polymorphism in the beta 1 adrenergic receptor gene, comprising administering to the patient (i) at least one antioxidant compound or a pharmaceutically acceptable salt thereof; (ii) at least one nitric oxide enhancing compound; and (iii) optionally the best current therapy for the treatment of cardiovascular diseases. In one embodiment the antioxidant is a hydralazine compound or a pharmaceutically acceptable salt thereof and the nitric oxide enhancing compound is isosorbide dinitrate and/or isosorbide mononitrate.
Genetic Risk Assessment In Heart Failure: Impact Of The Genetic Variation Of G-Protein Beta 3 Subunit Polymorphism
US Patent:
2009030, Dec 10, 2009
Filed:
Apr 4, 2007
Appl. No.:
12/296630
Inventors:
Manuel Worcel - Boston MA, US
Michael Sabolinski - Franklin MA, US
Sang W. Tam - Dover MA, US
Dennis M. McNamara - Venetia PA, US
Michael Sabolinski - Franklin MA, US
Sang W. Tam - Dover MA, US
Dennis M. McNamara - Venetia PA, US
Assignee:
NitoMed, Inc. - Lexington MA
Unversity of Pittsburgh of the Commonwealth System of the Higher Education - Pittsburgh PA
Unversity of Pittsburgh of the Commonwealth System of the Higher Education - Pittsburgh PA
International Classification:
A61K 31/56, A61K 31/34, A61K 31/502
US Classification:
514171, 514470, 514248
Abstract:
The invention provides methods for treating various indications and diseases in a patient in need thereof, wherein the patient has a C825T polymorphism in the G protein beta3 subunit (GNB3), comprising administering to the patient (i) at least one antioxidant compound or a pharmaceutically acceptable salt thereof; (ii) at least one nitric oxide enhancing compound; and (iii) optionally the best current therapy for the treatment of cardiovascular diseases. In one embodiment the antioxidant is a hydralazine compound or a pharmaceutically acceptable salt thereof and the nitric oxide enhancing compound is isosorbide dinitrate and/or isosorbide mononitrate.
Genetic Risk Assessment In Heart Failure: Impact Of The Genetic Variation Of Nos3
US Patent:
2009007, Mar 19, 2009
Filed:
Apr 7, 2006
Appl. No.:
11/887968
Inventors:
Manuel Worcel - Boston MA, US
Michael L. Sabolinski - Franklin MA, US
Sang William Tam - Dover MA, US
Dennis M. McNamara - Venetia PA, US
Michael L. Sabolinski - Franklin MA, US
Sang William Tam - Dover MA, US
Dennis M. McNamara - Venetia PA, US
Assignee:
NitroMed, Inc. - Lexington MA
University of Pittsburgh of the Commonwealth System of Higher Education - Pittsburgh PA
University of Pittsburgh of the Commonwealth System of Higher Education - Pittsburgh PA
International Classification:
A61K 31/58, A61K 31/34, A61K 31/502, A61P 9/00, A61P 17/00, A61K 31/40, A61K 31/403
US Classification:
514171, 514470, 514248, 514423, 514412
Abstract:
The invention provides methods for (a) reducing mortality associated with heart failure; (b) improving oxygen consumption; (c) treating heart failure; (d) treating hypertension; (e) improving the quality of life in a heart failure patient; (f) inhibiting left ventricular remodeling; (g) reducing hospitalizations related to heart failure; (h) improving exercise tolerance; (j) increasing left ventricular ejection fraction; (k) decreasing levels of B-type natriuretic protein; (l) treating renovascular diseases; (m) treating end-stage renal diseases; (n) reducing cardiomegaly; (o) treating diseases resulting from oxidative stress; (p) treating endothelial dysfunctions; (q) treating diseases caused by endothelial dysfunctions; (r) treating cardiovascular diseases; in a patient in need thereof, wherein the patient has at least one polymorphism in the endothelial nitric oxide synthase (NOS3) gene, comprising administering to the patient (i) at least one antioxidant compound or a pharmaceutically acceptable salt thereof; (ii) at least one nitric oxide enhancing compound; and (iii) optionally the best current therapy for the treatment of cardiovascular diseases. In one embodiment the antioxidant is a hydralazine compound or a pharmaceutically acceptable salt thereof and the nitric oxide enhancing compound is isosorbide dinitrate and/or isosorbide mononitrate.